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A B S T R A C T
A highly sensitive and convenient method for detecting inﬂuenza virus was developed using modiﬁed
end-point melt curve analysis of a RT-qPCR SYBR Green method and inﬂuenza virus-binding sugar chain-
immobilized gold-nanoparticles (SGNP). Because SGNPs capture inﬂuenza viruses, the virus-SGNP
complex was separated easily by centrifugation. Viral RNA was detected at very low concentrations,
suggesting that SGNP increased sensitivity compared with standard methods. This method was applied
to clinical studies. Inﬂuenza viruses were detected in saliva of patients or inpatients who had been
considered inﬂuenza-free by a rapid diagnostic assay of nasal swabs. Furthermore, the method was
applied to a human trial of prophylactic anti-inﬂuenza properties of yogurt containing Lactobacillus
acidophilus L-92. The incidence of inﬂuenza viruses in saliva of the L-92 group was found to be
signiﬁcantly lower compared to the control group. Thus, this method was useful for monitoring the
course of anti-inﬂuenza treatment or preventive measures against nosocomial infection.
ã2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Inﬂuenza virus infection is a common disease during Winter
and can causes pandemics such as the Spanish inﬂuenza pandemic
of 1918. Inﬂuenza virus infects the respiratory tract mucosa,
sometimes leading to severe illness and high mortality accompa-
nied by complications such as pneumonia [22]. Inﬂuenza virus
transmission among humans occurs every year, and is also thought
to be mediated by carriers who are infected but have no serious
symptoms [10]. Virulence is thought to involve a number of factors.
In the last century, four human inﬂuenza A virus pandemics have
emerged, at least three of which resulted from re-assortment of
human and animal inﬂuenza A viruses [14]. Presently, it is difﬁcult
to predict which inﬂuenza virus subtype will cause a pandemic. To
detect and prevent a new pandemic, it is important to detect the
virulent strain as soon as possible and suppress the risk of infection
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to a minimum. There are many relevant anti-viral drugs, such as
Oseltamivir, Zanamivir, and Peramivir. All of these are prescribed
after infection onset, which might be due to the lack of an efﬁcient
and convenient way to detect the low levels of the virus before the
onset. Furthermore, prescription of anti-virals to uninfected
individuals may lead to resistance. Therefore, easy, non-invasive,
and accurate diagnostic methods for testing of asymptomatic
patients with inﬂuenza are needed to reduce viral transmission.
At present, commercially available methods used for rapid
inﬂuenza diagnosis are antigen-based immunochromatographic
methods [23], which can detect the presence of virus using
antibodies for viral nuclear or structural proteins of each inﬂuenza
A or B. By these methods, the assay for the detection of inﬂuenza
viruses is completed within 30 min or less (duration of the
procedure), but their low sensitivity is a problem. Drexler et al.
reported that a common rapid antigen-based test detected virus in
only 11% of 144 clinical samples which were all conﬁrmed to be
inﬂuenza virus positive by means of PCR [2]. Uyeki and colleagues
reported that sensitivity of rapid diagnostic tests is low [19].
Although the sensitivity of the antigen-based immunochromato-
graphic methods is improving, these methods still cannot detect
virus even in severely ill patients, who are likely to be heavily
infected. Polymerase chain reaction (PCR) methods have been
proposed to improve sensitivity. The PCR methods, however, also
have shortcomings because they require special equipment, highly
skilled personnel, a lengthy procedure, and tedious extraction of
RNA, compared to antigen-based immunochromatographic meth-
ods. Recently, Kawai and co-workers applied the RT-SmartAmp
assay to rapidly detect inﬂuenza virus in patients’ nasal swabs in
40 min without any cross-reaction with other relevant viruses [6].
In addition, some groups have published results on inﬂuenza virus
detection using non-PCR-based ampliﬁcation technologies, such as
RT-LAMP, which can be completed in less than 60 min [25]. Thus, in
principle, inﬂuenza virus detection methods based on cDNA have
nearly reached the status of rapid detection, with higher sensitivity
compared to antigen-based methods. Nevertheless, there are still
difﬁculties with easy and non-invasive collection of samples from
asymptomatic patients, which may be the key to prevent inﬂuenza
epidemics/pandemics. In addition, infants, pregnant women, the
elderly, and patients with diseases such as diabetes, cancer, or
immunodeﬁciency, are especially prone to severe inﬂuenza illness,
and therefore methods for pre-morbid detection are urgently
needed.
A sugar chain-immobilized chip, named Sugar Chip (SC), and
sugar chain-immobilized gold nanoparticles (SGNPs) were previ-
ously developed [21,9]. In brief, sugar chains obtained from a
natural source or via chemical synthesis were conjugated with an
original linker molecule to prepare a linker-containing sugar chain
(deﬁned as ‘sugar chain’ ligand-conjugate), and then the sugar
chains were immobilized on either the gold chip (to prepare SC) or
on gold nanoparticles (to prepare SGNP). SC can serve as a sensor
chip in a surface plasmon resonance (SPR) device for high-
throughput analysis of proteins because the binding interaction
with SPR can be evaluated without any labeling of proteins. SGNPs
are used for visual detection because SGNPs lose the plasmon
absorption ability when the interaction occurs between sugar
chains on SGNP and analytes in a solution. SGNPs are also useful for
capture and concentration of viruses [26].
In this study, a new highly sensitive test for inﬂuenza virus in
saliva was developed. The method involves capture and concen-
tration of the viral particles with SGNP in combination with the
inexpensive and convenient RT-qPCR SYBR Green method
(RT-qPCR-SYBR). Sugar chains can serve as a receptor molecule
for the virus [1,12,18]. For example, inﬂuenza viruses bind to
neuraminic acid-containing oligosaccharides on the cell surface at
the ﬁrst stage of infection using hemagglutinin (HA) proteins on
the surface of the virus. We previously analyzed the afﬁnity of
binding of 242 strains of inﬂuenza virus to oligosaccharides, using
surface plasmon resonance (SPR) imaging and our SC immobilized
with various sugar chains containing either anionic or neutral
moieties. From the 242 strains of inﬂuenza virus, 1976 data sets
were obtained, a database was created, and an algorithm was
developed, based on the nearest neighbor with Euclidean distance
approach to identify the strains most similar in their relative
afﬁnity for sugar chains. Based on the database and the algorithm,
an inﬂuenza virus strain was identiﬁed that was most similar to the
2009 pandemic virus (H1N1pdm2009) obtained from clinical
isolates. In addition, based on the binding data, heparin, a sulfated
polysaccharide, was shown to bind to every inﬂuenza virus, which
allowed preparation of heparin- or dextran sulfated oligosaccha-
ride-immobilized gold nanoparticles. After that, a novel method
for sensitive detection of inﬂuenza viruses was established using
the nanoparticles in combination with the reverse transcription
real-time quantitative PCR (RT-qPCR) SYBR Green method [17].
In the present work, the new method was applied to 2 clinical
studies involving saliva samples from patients who visited the
hospital or children’s clinic and from inpatients. The utility of the
assay in comparison with the conventional immunochromato-
graphic method (rapid kit) was evaluated using nasal swabs. The
utility of our method was tested in a human trial in healthy
Japanese adults to evaluate the prophylactic effect of yogurt
containing Lactobacillus acidophilus strain L-92 against inﬂuenza
virus infection and inﬂuenza-like symptoms during the winter
season.
2. Materials and methods
2.1. Synthesis of SGNP
Two kinds of SGNP were prepared: {1} immobilized with
heparin (Hep-GNP) or {2} immobilized with low molecular weight
(MW = 2500) dextran sulfate (DS25-GNP) according to previous
reports [15,16,21,9] with slight modiﬁcations. In brief, to synthesize
Hep-GNP, 1 mL of aqueous solution of sodium citrate (16.2 mM)
was added to 9 mL of aqueous NaAuCl4 (1.1 mM) with stirring at
100 C. Then, the heparin-linker conjugate (‘heparin’ ligand-
conjugate, heparin-mono, 12 mg) was added to the solution with
gentle stirring, and the mixture was further stirred for 1 h at 25 C
in the dark. The solution was centrifuged at 12,000 g for 40 min to
obtain a precipitate. After several washes with double distilled
water (ddH2O), the precipitate was re-suspended in ddH2O, and
adjusted to A530 = 5.0 (a 10-mm equivalent of absorbance) to obtain
Hep-GNP.
To synthesize DS25-GNP, 50 mM of sodium tetrahydroborate
(10 mL) was added to 1.3 mM NaAuCl4 (38 mL) with stirring at 4 C.
Then, the linker-dextran sulfate conjugate (‘low molecular weight
dextran sulfate's ligand conjugate, DS25-mono, 22.5 mg) was
added to the solution, and incubated with gentle stirring for 1 h at
4 C in the dark. The solution was dialyzed against ddH2O using a
dialysis membrane with MW 3500 cutoff and then lyophilized. The
lyophilized powder was re-suspended in ddH2O and adjusted to
10 mg/mL. Then, sequential centrifugation was performed at
12,000  g for 15 min to obtain the precipitate. The precipitate
was re-suspended in ddH2O, and adjusted to 1 mg/mL with ddH2O
to obtain DS25-GNP. The content of heparin or low molecular
weight dextran sulfate was evaluated using the ABEE method [24];
heparin content was 2% in Hep-GNP, and the content of low
molecular weight dextran sulfate was 9% in DS25-GNP. The size of
nanoparticles in ddH2O was measured using DLS (Zeta-Sizer Nano-
ZS, Melbane, Kobe, Japan); Hep-GNP particles had a diameter of
62.0  3.4 nm, whereas DS25-GNP’s diameter was 62.4 16.4 nm,
on average.
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2.2. Virus preparation and construction of plasmids
As a quantitative control for real-time PCR, control plasmid DNAs
were prepared. The RT-PCR products derived from clinical isolates of
inﬂuenza viruses (type A: A/Okuda/57, or A/H1N1pdm09; type B:
B/Osaka/304/2007) were synthesized using the primer sets de-
scribed below using PrimeScript One Step RT-PCR Kit Version 2
(Takara Bio Inc., Otsu, Japan). The RT-PCR products were puriﬁed
using NucleoSpin Gel and PCR Clean-up (Macherey-Nagel GmbH &
Co., Germany) and ligated into the pGEM-T Easy Vector (Promega,
Germany). The plasmid vectors were introduced into DH5a
Escherichia coli cells, which were grown in a culture medium, and
plasmid DNA was puriﬁed using the NucleoSpin Plasmid kit
(Macherey-Nagel GmbH & Co.). The control plasmid DNA was
quantiﬁed using OD260 measurement, and a series of 10-fold
dilutions was prepared (from 108 to 100 copies/mL) and tested by
means of the RT-qPCR SYBR Green assay.
2.3. RT-qPCR conditions and evaluation criteria
The RT-qPCR SYBR Green assay was carried out using a Thermal
Cycler Dice Real Time System (Takara Bio Inc.) with a commercial
reagent (One-Step SYBR Prime Script RT-PCR Kit 2 (Perfect Real
Time), Takara Bio Inc.) according to the manufacturer’s instruc-
tions. Primers for these reactions were designed for the gene
encoding the M protein of inﬂuenza virus type A and the NS protein
of type B inﬂuenza virus as follows: type A forward 50 GGA CTG CAG
CGT AGA CGC TT, reverse 50 CAT YCT GTT GTA TAT GAG GCC CAT;
type B forward 50 AAA TAC GGT GGA TTA AAT AAA AGC AA, reverse
50 CCA GCA ATA GCT CCG AAG AAA [20]. The RT-qPCR protocol
consisted of 45 C for 5 min, 95 C for 10 s, and 40 cycles of 95 C for
5 s and 60 C for 30 s. The identity of the ampliﬁed product was
veriﬁed using the melting curve analysis (denaturation at 95 C for
15 s followed by stepwise elevation of the temperature from 60 C
to 95 C by 0.5 C in 30-s increments). Ct (threshold cycle)
corresponded to the cycle number at which the ﬂuorescence
signiﬁcantly exceeded the background.
2.4. Virus detection in saliva (clinical samples)
Two clinical studies were designed at Kagoshima University
Hospital, Murakami Clinic for Children, and Hyogo College of
Medicine Hospital. At the Kagoshima University Hospital and
Murakami Clinic for Children in 2011–2012, saliva samples were
collected from patients (total number 183; under the age of 16:109,
over the age of 16:74) who visited the hospital or clinic because
of a fever or ﬂu-like symptoms. This study was reviewed and
approved by the Kagoshima University Hospital Ethical Committee
(No. 23–140); written informed consent was obtained from each
subject’s parents/guardians before study entry. All patients were
also tested by means of a conventional immunochromatographic
method (rapid kit, Clearline-Inﬂuenza-A/B/(H1N1) 2009, Meiji
Seika Pharma Co., Ltd., Tokyo, Japan, or QuickNaviTM-Flu Otsuka
Pharmaceutical Co., Ltd., Tokushima, Japan) using their nasal
swabs. At the Hyogo Medical College Hospital in 2012–2013, saliva
samples were collected from inpatients (total number was 55) who
either had or did not have ﬂu-like symptoms; these patients had
been treated for other diseases or received surgical care in the
hospital. The study was reviewed and approved by the ethics
committee of Hyogo Medical College Hospital (No. 783). All
subjects read and signed informed consent forms before study
entry. Nasal swab samples of 24 inpatients were also tested using
the rapid kit (ESPLINE1 Inﬂuenza A and B–N, Fujirebio Inc., Tokyo,
Japan).
Fig. 1. Subject recruitment and retention.
Subject recruitment and retention is described.
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Approximately 0.5 mL of saliva was collected from symptomatic
or asymptomatic patients/inpatients using a dropper and trans-
ferred to the collection tube by patients themselves when the
patients/inpatients were in the hospital. The collected saliva
samples were stored at 4 C after being mixed with 0.5 mL of MEM
medium containing 1% penicillin–streptomycin solution (abbrevi-
ated as PS, NacalaiTesque, Japan) or PBS containing 1% PS without
divalent cations. Within 6 h, after centrifugation at 10,000  g for
2 min at 4 C to remove debris in saliva samples, 500 mL of the
supernatant was mixed with 10 mL of SGNP (Hep-GNP or DS25-
GNP) and incubated for 30 min at room temperature in the dark
with gentle agitation. After that, the reaction mixture was
centrifuged at 10,000  g for 10 min at 4 C to obtain a precipitate
containing SGNP and viruses. The precipitate was washed with
500 mL of PBS and centrifuged again at 10,000  g for 10 min at 4 C.
The resulting precipitates were re-suspended in 10 mL of RNase-
free water, and heated at 100 C for 10 min to disrupt viral particles
and release viral RNA that was used for RT-qPCR.
2.5. Virus detection in saliva in a human trial
The study protocol was approved by the Ethical Committee of
Calpis Co., Ltd., registered under number 5 and Ethical Committees
of Shiba Palace Clinic in Tokyo, Japan, registered under KRPS-
10887, and this trial was performed according to the Declaration of
Helsinki on Human Rights.
This study was conducted during the winter season, between
December 2010 and February 2011. 227 Japanese healthy
volunteers agreed to participate in this study by the SOUKEN
Co., Ltd., according to previous trial [8]. Exclusion criteria were
as follows: (a) those believed to be ingesting a drug that may
inﬂuence test results (b) those who were vaccinated one year
previously (c) those who were diagnosed with inﬂuenza one
year previously (d) those believed to be routinely ingesting
health food that may inﬂuence test results e.g., food containing
lactic acid bacteria (e) those judged as being disqualiﬁed to
participate in this test by a leading physician au fait with the
test. In regard to characteristics of subjects, all volunteers
enrolled in this trial had no cold-like symptoms at the
beginning of the trial and lived in the same area throughout
the experiment. Six volunteers were excluded because they
declined to participate. All volunteers read and signed informed
consent forms. 111 subjects were assigned to the test group
who, once a day for 8 weeks, consumed 100 g of the commercial
product Nyusankin-Seikatsu Yogurt containing Lactobacillus aci-
dophilus L-92 (at least 1010 cells) provided by Calpis Co., Ltd.
(Tokyo, Japan). One hundred and ten subjects who did not take
yogurt for 8 weeks were assigned to the control group.
Randomization was performed by the study statistician using
a computer generated code. Study design and a ﬂow diagram is
shown in Fig. 1. All participants were asked to avoid an irregular
lifestyle (lack of sleep, over-eating, and over-drinking alcohol)
during the whole study period. In addition, intake of products
with components known to have an immunostimulatory effects,
such as Lactobacillus, was prohibited during the test period. The
subjects reported relevant signs and symptoms, such as body
temperature, and a score for 13 questions about ﬂu-like
symptoms and preventive measures, every morning after
awakening.
Approximately 0.5 mL of saliva specimens were collected from
the volunteers using a dropper in the morning, every 7 days. The
saliva samples were stored at 4 C after being mixed with 0.5 mL of
MEM medium containing 1% PS. Within 2 days, the sample solution
was tested as described above. If a subject was judged to be
unsuitable for data analysis for any valid reason (e.g., non-
compliance with the prescribed dose, failure to follow instructions
and virus testing before the trial), the subject was excluded from
data analysis. Statistical signiﬁcance was determined using the log
Fig. 2. Ct and RI values of inﬂuenza virus in the RT-qPCR SYBR Green method.
The standard curve of the threshold cycle (Ct) and relative intensity values (RI) of type A inﬂuenza (panels A, B) and type B inﬂuenza (panels C, D). The culture supernatant of
inﬂuenza virus (type A: A/Okuda/57, type B: B/Osaka/304/2007) was diluted to the 0.5, 1, 2, 4, 7, 10, 100, 1000, and 10,000 copies per sample. Three independent experiments
were performed in triplicate.
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rank test or Mann–Whitney U-test and accepted as p < 0.05.
Statistical analysis was performed using SPSS Version 20.0 (SPSS
Inc., Chicago, IL, USA).
3. Results and discussion
3.1. Development of the sensitive and accurate semi-quantitative
evaluation method for the RT-qPCR SYBR Green method
To semi-quantitatively evaluate the results of the RT-qPCR SYBR
Green method with the low copy numbers of viral RNA, a
convenient and accurate method was developed. In the standard
RT-qPCR analysis, the presence of the target RNA is quantiﬁed
using the threshold cycle number (Ct value). On the other hand,
when the quantity of target RNA is low, the SYBR Green method
needs careful comparison of the Tm (melting temperature) curve
with that of a positive control. This approach means that the
quantiﬁcation based on the Tm curve is a more conventional and
accurate evaluation technique for the results of qPCR of the SYBR
Green method than the Ct value, especially at low RNA copy
numbers. In our method, after 40 cycles of PCR, the temperature
increased from 60 to 95 C stepwise by 0.5 C every 30 s to monitor
how the dsDNA (PCR product) melted into ssDNA with a drop in
ﬂuorescence as the dye (SYBR Green I) becomes inactive. The
melting curve is converted to a distinct melting peak by plotting
the ﬁrst negative derivative of the ﬂuorescence (dF/dT) as a
function of the temperature. First, using a positive control, which
was the PCR product of 10,000 copies of plasmid cDNA with the
forward/reverse primers in a PCR reaction, melting point, Tm (the
temperature at the greatest absolute value of dF/dT) was
determined. Then, the temperature points Tm 0.5 C, and
Tm + 1.0 C or 1.0 C (with greater absolute value of dF/dT) were
determined. The absolute values of dF/dT of the 4 temperature
points (Tm,Tm + 0.5 C, Tm–0.5 C, Tm + 1.0 C or 1.0 C), were
summed up to obtain the total value A. Using the negative control
(ddH2O), the absolute values of dF/dT of the 4 temperature points
determined in the positive control were also calculated to obtain
the total value B. Similarly, the absolute values of dF/dT of the
same 4 temperature points measured in the sample were
calculated to obtain the total value of C. Using A, B, and C, the
relative intensity (RI) of a sample was determined as follows:
RI ¼ ðC  BÞðA  BÞ  100%
It is crucial that the temperature of the greatest absolute value of
dF/dT of the sample is within 0.5 C of the Tm for the positive
control.
In Fig. 2, the Ct values and RI values of control samples datasets,
(culture supernatant of inﬂuenza virus A/Okuda/57 and B/Osaka/
304/2007), were plotted against the virus copy number. The copy
number of the culture supernatant of each virus was determined
by comparing the Ct value at the high concentration with that of
the target cDNA containing a plasmid. We found that the detection
limit of RI for type A inﬂuenza virus was 1% of RI, and calibration
was possible (reproducible) over 4% of RI. On the contrary, the
threshold of type B inﬂuenza virus was 3%, and the calibration was
possible over 10% of RI. However, the primers for type B may not be
adequate, according to these data. Thus, we established 3 semi-
quantitative categories for each type of inﬂuenza virus as follows:
type A: plus RI  4%, plus-minus 1%  RI < 4%, minus RI < 1%; type
B: plus RI  10%, plus-minus 3%  RI < 10%, minus RI < 3%. The PCR
products of the control and clinical samples after concentration
with SGNP as follows were also analyzed in part by agarose gel
(Fig. S1).
4.1. An increase of sensitivity in buffer and in saliva
An outline of the assay using SGNP and saliva samples is shown
in Fig. 3, where 500 mL of a sample solution was concentrated to
10 mL, suggesting that a 50-fold increase in sensitivity was
achieved, in theory. The Ct (threshold cycle) values of RT-qPCR-
SYBR were compared between the conditions with and without
SGNP treatment of the culture supernatant.
As shown in Table 1, the Ct values for samples of culture
supernatant diluted (100, 1000, 10,000, and 100,000) with
PBS were 21.31, 25.41, 30.31, and 32.98 with SGNP (Hep-GNP)
treatment and 26.25, 30.39, 33.63, and 36.62 without SGNP
treatment, respectively. This observation means that the viral
particles were concentrated 23–25 times (8- to 32-fold) by Hep-
GNP. In addition, with DS25-GNP, the Ct values were 20.99, 26.10,
29.88, and 33.43 compared with 26.68, 30.70, 33.27, and 37.13,
suggestive of concentration by a factor of 23.–26 times (10- to
54-fold). The Ct values of extracted RNA from the same diluted
sample using an RNA extraction kit were almost identical to those
obtained with SGNP concentration procedure. The above data
suggest that SGNPs captured and concentrated viral particles as
Fig. 3. The schematic of our concentration method using SGNP and saliva samples.
Approximately 0.5 mL of saliva is collected from symptomatic or asymptomatic patients/inpatients using a dropper and mixed with 0.5 mL of MEM medium or PBS containing
1% penicillin-streptomycin mixed solution. After centrifugation at 10,000  g for 2 min at 4 C to remove debris from the saliva sample, 500 mL of the supernatant is mixed
with 10 mL of SGNP and incubated for 30 min at room temperature in the dark with gentle agitation. Then, the reaction mixture is centrifuged at 10,000  g for 10 min at 4 C to
obtain a precipitate containing SGNP and inﬂuenza virus. The precipitate was washed with 500 mL of PBS and centrifuged again at 10,000  g for 10 min at 4 C. The resulting
precipitate was re-suspended in 10 mL of RNase-free water, and heated at 100 C for 10 min to destroy viral particles and release viral RNA that is used for RT-qPCR.
Table 1
Ct values of inﬂuenza virus with or without the use of SGNPs and the extracted RNA.
Ct values of RT-qPCR SYBR Green method
DS25-GNP Hep-GNP Extracted RNA
Dilution of virus (-fold) With Without With Without
100 20.99 26.68 21.31 26.25 20.65
1000 26.10 30.70 25.41 30.39 26.16
10000 29.88 33.27 30.31 33.63 27.27
100000 33.43 37.13 32.98 36.62 33.06
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effectively as an RNA extraction method, and the difference in
efﬁciency between Hep-GNP and DS25-GNP was negligible.
After that, similar in vitro experiments were conducted, where
the virus culture supernatant of the strain A/H1N1pdm09 was
mixed with saliva from a healthy volunteer. In Table 2, the effects of
SGNP seem to be similar to the ones described above. The Ct values
decreased (sensitivity increased) when the sample mixture was
treated with Hep-GNP, even though the Ct values in the saliva were
greater than those in PBS. This difference was most likely due to the
inhibitors of PCR in saliva, such as gp340 [7], which is a highly
anionic polymer containing many neuraminic acid residues
(mucin). The values of RI of SGNP-treated samples were all
increased compared with those of the starting sample mixture
(without SGNP), even if 50% saliva was present in the sample
mixture, where viral RNA remained in the supernatant. This result
suggests that mucin in saliva has an inhibitory effect on the binding
of virus to SGNP. Although the inhibitory effect was appreciable,
the capture and concentration with SGNP was sufﬁcient for use
with our method in clinical study or in a human trial. Thus, our
method was used for further experimentation.
4.2. Clinical study
Our sensitive detection method, including the analytical
modiﬁcation, was applied to a clinical study at Kagoshima
University Hospital, Murakami Clinic for Children, and Hyogo
College of Medicine Hospital.
In season 2011–2012, a total of 183 patients were enrolled in the
study (<16 years old: 109; older than 16 years: 74) including
medical doctors and nurses at Kagoshima University Hospital or
outpatients who visited Murakami Clinic for Children because of
ﬂu- or cold-like symptoms. In addition to saliva, nasal swab
samples were taken from all patients and tested using the antigen-
based immunochromatographic assay (rapid kit). Because the
purpose of this clinical research was to detect symptoms in
patients, only the plus categories of RI in our method were
analyzed and compared with the diagnostic results obtained with
the nasal swabs and the rapid kit (Table 3). It was surprising that
inﬂuenza viruses in 52% (24/46) of adult patients and 57% (26/46)
of childhood patients were detected by our method using saliva
and RT-qPCR, but were not detected in the 46 adult and
46 childhood patients by the rapid kit with the nasal swab. From
the large difference in sensitivity between RT-qPCR and the rapid
kit [2], the results described above might be reasonable if nasal
swabs were used as samples for our method. However, since the
concentration of inﬂuenza viral particles in saliva is much lower
than in nasal swabs [11], the data using saliva samples suggested
that our technology was both useful and effective.
The second clinical study was conducted at Hyogo College of
Medicine Hospital during the 2012–2013 season. An outbreak of
inﬂuenza occurred during the winter of 2012–2013 where
16 inpatients received a diagnosis of inﬂuenza according to the
rapid diagnostic kit in 2 independent wings of the hospital, within
4 days. Saliva samples were obtained from 55 inpatients who had
or did not have ﬂu-like or cold-like symptoms; these patients had
been treated for other diseases or received surgical care in the
hospital. Twenty four inpatients out of 55 agreed to provide a nasal
swab, which was tested using the rapid kit. Because the purpose of
this clinical research was to ﬁnd symptoms in inpatients, only plus
categories of RI in the developed method were analyzed.
As shown in Table 4, this method showed that 5 of 33 inpatients
who did not have ﬂu-like symptoms carried inﬂuenza virus RNA in
their saliva, suggesting that they were asymptomatic patients with
inﬂuenza virus. In addition, 5 of 9 inpatients who had been
diagnosed as negative by the rapid kit were found to have inﬂuenza
viral RNA in their saliva (Table 5) according to our method. These
data suggest that the rapid kit generated some false-negative
results in symptomatic inﬂuenza patients due to low sensitivity.
Because those asymptomatic inpatients were in a controlled
environment and received timely treatment, according to the
results above, the method using saliva may contribute to the
prevention of onward infection or terminate nosocomial out-
breaks.
The diagnosis of inﬂuenza is ascertained by culturing/isolation
of virus, or serological tests, or PCR method. To corroborate the
data, other virus detection methods such as virus isolation should
be compared. However, at present, diagnosis needs to be more
rapid to treat patients more promptly, and therefore, the rapid test
is commonly used for inﬂuenza virus detection. Our new
developed method was compared with a rapid test in this study.
Table 2
A concentration procedure for culture supernatant of H1N1pdm09 type A inﬂuenza
virus containing human saliva by means of Hep-GNP.
Ratio of saliva (%) Dilution of virus (fold) Hep-GNP
With Without
Ct RI (%) Ct RI (%)
50 1000 28.33 76.80 31.44 59.87
10,000 31.36 63.15 36.04 32.74
–
25 1000 29.10 82.09 36.93 23.56
10,000 30.02 79.45 36.62 24.48
–
10 1000 26.21 98.58 35.03 47.64
10,000 29.66 90.43 36.83 26.10
–
0 1000 19.11 105.87 28.89 76.70
10,000 23.16 85.39 31.85 63.48
Table 3
Comparison between the rapid kit using nasal swabs and the SGNP-concentration/RT qPCR SYBR Green method in saliva.
Patients Rapid kit using nasal swab Our method using saliva
A+ B+ –
Adults A+ 25 25 0 0
B+ 3 1 2 0
– 46 24 0 22
–
Children (under 16 years old) A+ 56 54 0 2
B+ 7 1 4 2
– 46 23 3 20
Table 4
Diagnostic results of inpatients using our SGNP-concentration/RT qPCR SYBR Green
method: comparison of symptoms.
Symptoms Our method using saliva
Type A positive (%) Negative (%)
Flu-like 22 20 (90.9) 2 (9.1)
No 33 5 (15.2) 28 (84.8)
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For future analysis, a large-scale follow-up cohort study to
clarify usability of our new method should be conducted. For
example, it might be possible to investigate how many asymp-
tomatic healthy subjects are found to have inﬂuenza viral RNA in
saliva by our method and who develop the symptoms of inﬂuenza
thereafter.
4.3. Detection of inﬂuenza viruses in the human trial
Using this newly developed method, a human trial of the anti-
inﬂuenza effect of yogurt containing Lactobacillus acidophilus
L-92 was conducted, which was previously shown to have an anti-
viral effect in laboratory animals [3] and anti-allergy properties in
both humans and animals [4,5,13]. In such a human trial, recruiting
a signiﬁcant sample size of subjects is problematic because the
average percentage of symptomatic inﬂuenza patients is usually
less than 10% of the general population. Therefore, it would be
better to evaluate asymptomatic cases at high sensitivity. Testing
the method for collecting samples is also important. Getting saliva
samples every week was straightforward, but obtaining nasal
swabs every week was difﬁcult due to the uncomfortable
procedure. Our method matches the above criteria. Because the
purpose of the study was to make an accurate diagnosis in
asymptomatic and symptomatic patients as far as possible, both
plus and plus-minus categories of RI were analyzed in this
experiment.
A total of 221 subjects who had a tendency to fall ill during the
winter season were selected and assigned randomly to 2 groups
with the following demographics: the L-92 group (n = 111; males:
42, females: 69; average age: 41.0  7.7 [mean  SD]) and the
control group (n = 110; males: 36, females: 74; average age:
41.0  7.0). This study was conducted during the winter season,
between December 2010 and February 2011, and no adverse events
speciﬁc to L-92 was observed throughout the whole test period.
Type A or B inﬂuenza viruses were detected from 17 subject’s saliva
despite the fact that they had no cold-like symptoms at the
beginning of the trial. The analysis excluded these 17 subjects but
revealed that the rate of the subjects who had type A inﬂuenza
virus RNA in their saliva was increased in both groups during the
test period after starting the trial in January (Fig. 4A). This suggests
that type A inﬂuenza was circulating in Japan at epidemic levels.
The following participants tested positive for the inﬂuenza virus
RNA eight weeks after the onset of treatment: 25% of the control
group and 16% of the L-92 group. The percentage of people of
which inﬂuenza type A viruses were detected in the L-92 group
was signiﬁcantly lower than that in the control group (p < 0.05)
(Fig. 4A). On the other hand, no difference in type B inﬂuenza virus
infection was observed between the 2 groups (and the detection
rate was low; Fig. 4B). The data suggested that there was no
evidence of a type B inﬂuenza epidemic happening in Japan at the
time. To evaluate the severity of ﬂu-like symptoms, body
temperature during initial awakening was measured every day
in the morning. The number of subjects whose body temperature
in the morning was above 38 C (which indicates severe
symptoms) was 2 of 111 subjects in the L-92 group and 10 of
110 subjects in the control group (p < 0.01, x2 test). In addition,
most of the subjective symptom scores, such as the degree of
throat soreness, frequency of coughing, fatigue, chills, and
hoarseness, were signiﬁcantly lower in the L-92 group compared
to the control group (Fig. S2).
No signiﬁcant differences were found in 3 questionnaires
relating to preventive measures other than the rest time
throughout this test period in the L-92 group compared to the
control group (data not shown). According to the above data, it
seems that the developed method was applicable not only in
detecting inﬂuenza virus at early stage, but could evaluate
preventive effects on virus infection in the development of drugs
or functional foods. As for L-92, it was recently demonstrated that
continuous oral administration of L-92 for 2 weeks suppressed the
viral titer and activated NK cells in lungs of mice infected with
inﬂuenza virus [3]. Therefore, L-92 may have the potential to
promote vigorous host immune responses. In this clinical study,
supplementation of L-92 is considered useful for prevention of
inﬂuenza, although a double blinded, placebo-controlled trial was
not performed. In order to conﬁrm the effect of L-92 on prevention
of inﬂuenza virus infection, another study must be performed.
L-92 is easily applicable in various food products, such as beverages
Table 5
Diagnostic results of inpatients using our SGNP-concentration/RT qPCR SYBR Green
method: comparison with the rapid kit.
Rapid kit Our method using saliva
Type A positive (%) Negative (%)
Type A positive 15 13 (86.7) 2 (13.3)
Negative 9 5 (55.6) 4 (44.4)
Fig. 4. Detection of inﬂuenza virus in the L-92 group and control group by means of SGNP-concentration/RT qPCR SYBR Green method.
Time course of the number of subjects in the L-92 group and the control group who tested positive for inﬂuenza virus type A (panel A) and type B (panel B) in saliva during
8 weeks. The subjects gave their saliva samples every 7 days and inﬂuenza virus was detected in saliva using our newly developed method. Regarding inﬂuenza virus type A,
statistical signiﬁcances between the 2 groups were calculated using the Kaplan–Maier log rank test.
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and supplements. If the promotion of host immune response by
L-92 is conﬁrmed in well-designed human studies, daily intake of
the food products containing L-92 might be one of the easy
approaches to prevent viral infection.
In the present study, a highly sensitive, accurate, convenient,
and non-painful method for inﬂuenza virus detection using saliva
was proposed with a nano-biotechnology and inexpensive
RT-qPCR CYBR Green method. According to this new method,
false-negative diagnostic results of the antigen-based rapid kit
were suggested in the patients; this ﬁnding helped to initiate
appropriate and early treatment of the patients. In addition, the
newly developed method might be helpful in preventing
nosocomial infection with inﬂuenza virus by ﬁnding asymptomatic
patients at an early stage. The method has also been applied to a
human trial of L. acidophilus L-92 strain in protecting against
inﬂuenza virus infection in approximately 200 volunteers.
In conclusion, because the new method was able to detect trace
amounts of inﬂuenza virus, the method may be used in a variety of
applications, such as testing for nosocomial infection or detection
of bioterrorism efforts. This test may decrease the cost of medical
care via early treatment of asymptomatic patients and may prevent
the loss of labor productivity and the resultant losses to the
economy.
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